In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 1, 2008, Pages 156-160

  Tsuji, Brian T ^a,b   Yang, Jenny C ^a   Forrest, Alan ^a   Kelchlin, Pamela A ^a   Smith, Patrick F ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Benzoxazinorifamycin; Rifalazil; S. aureus

Indexed keywords

ABI 0043; METICILLIN; RIFAMYCIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; IN VITRO STUDY; MATHEMATICAL MODEL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHICILLIN RESISTANCE; MICROBIAL VIABILITY; RIFAMYCINS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 45749148719     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn133     Document Type: Article

References (12)

1. Fujii K, Saito H, Tomioka H et al. Mechanism of action of anti-mycobacterial activity of the new benzoxazinorifamycin KRM-1648. Antimicrob Agents Chemother 1995; 39: 1489-92.
2. Murphy CK, Mullin S, Osburne MS et al. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 827-34.
3. Rothstein DM, Farquhar RS, Sirokman K et al. Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection. Antimicrob Agents Chemother 2006; 50: 3658-64.
4. Lee SY, Tessier PR, Murphy CK et al. Bactericidal efficacy of ABI-0043, a novel rifamycin, in a murine pneumococcal pneumonia model. J Antibiot (Tokyo) 2006; 59: 804-7.
5. Trampuz A, Murphy CK, Rothstein DM et al. Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. Antimicrob Agents Chemother 2007; 51: 2540-5.
6. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
7. Rothstein DM, Shalish C, Murphy CK et al. Development potential of rifalazil and other benzoxazinorifamycins. Expert Opin Investig Drugs 2006; 15: 603-23.
8. Flamm RK, Karginova E, Rothstein DMDM et al. In vitro potency and spectrum of novel rifamycins ABI-0043, ABI-0094 and ABI-0299. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, 2005. Abstract F-2043, p. 222. American Society for Microbiology, Washington, DC, USA.
9. Zavasky DM, Sande MA. Reconsideration of rifampin: A unique drug for a unique infection. JAMA 1998; 279: 1575-7.
10. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-80.
11. Eng RH, Smith SM, Tillem M et al. Rifampin resistance. Development during the therapy of methicillin-resistant Staphylococcus aureus infection. Arch Intern Med 1985; 145: 146-8.
12. Chen Y, Larsson M, Pieniaszek et al. The pharmacokinetics of ABI-0043, a novel rifamycin antibacterial, in healthy beagle dogs and male Sprague-Dawley rats following oral and intravenous administration. In: Abstracts of the Forty-fifth Inferscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, 2005. Abstract F-2047, pp. 223-4. American Society for Microbiology, Washington, DC, USA.